Skip to main content
Premium Trial:

Request an Annual Quote

HistoRx Extends Eli Lilly Deal for Biomarker Analysis Technology

NEW YORK (GenomeWeb News) – HistoRx said today that it has signed a three-year agreement to supply its biomarker analysis technology to drugmaker Eli Lilly and Company.

The company said it has extended and expanded a 2005 agreement to make its Aqua technology available to Lilly for use in its pharmaceutical development programs.

Under the agreement, HistoRx will give Lilly’s researchers access to the biomarker analysis technology and it will develop customized immunohistochemical assays for use in Lilly’s drug programs. HistoRx also gains the option to commercialize the assays and reagents that are developed over the course of the partnership for use as predictive diagnostics.

Financial terms of the agreement were not released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.